Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development. Particularly, we offer our clients a special pipeline of antigen-specific TCR-T cells generation in terms of the method of direct targeting of human tumors using autologous TILs to meet your needs.
The generation of T lymphocytes with specific reactivity against tumor antigens is a prerequisite for effective adoptive transfer therapies. Adoptive immunotherapy using the transfer of viral-antigen-specific T cells is now a well-established procedure that results in effective treatment of transplant-associated viral infection and rare viral-related malignancies. The direct targeting of human tumors using autologous tumor-infiltrating lymphocytes (TILs) was first demonstrated in 1988. There Administration of ex vivo cultured, naturally occurring TILs has been shown to mediate durable regression of tumors. However, limitation of TIL therapy includes the requirement for surgery to isolate the tumor, as well as the ability to generate consistently T cells with antitumor activity.
Therefore, Creative Biolabs has optimized the approach of targeting of human tumors in the use of autologous TILs of gene technology to transform T cells to express tumor-specific antigen receptors. In other words, TCRs can be cloned from naturally occurring T cells by using gene transfer vectors and introduced into patient’s lymphocytes. Thus, it can be generated large quantities of antigen-specific TCR-T cells for treatment by using our pipeline.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE